Your browser does not allow JavaScript!
JavaScript is necessary for the proper functioning of this website. Please enable JavaScript or use a modern browser.
Open Science Slovenia
Open Science
DiKUL
slv
|
eng
Search
Browse
New in RUL
About RUL
In numbers
Help
Sign in
Identifying the steps required to effectively implement next-generation sequencing in oncology at a national level in Europe
ID
Horgan, Denis
(
Author
),
ID
Čufer, Tanja
(
Author
), et al.
PDF - Presentation file,
Download
(2,39 MB)
MD5: 8BECBE0CEC16582C29500F1EF05DE0C4
URL - Source URL, Visit
https://www.mdpi.com/2075-4426/12/1/72
Image galllery
Abstract
Next-generation sequencing (NGS) may enable more focused and highly personalized cancer treatment, with the National Comprehensive Cancer Network and European Society for Medical Oncology guidelines now recommending NGS for daily clinical practice for several tumor types. However, NGS implementation, and therefore patient access, varies across Europe; a multi-stakeholder collaboration is needed to establish the conditions required to improve this discrepancy. In that regard, we set up European Alliance for Personalised Medicine (EAPM)-led expert panels during the first half of 2021, including key stakeholders from across 10 European countries covering medical, economic, patient, industry, and governmental expertise. We describe the outcomes of these panels in order to define and explore the necessary conditions for NGS implementation into routine clinical care to enable patient access, identify specific challenges in achieving them, and make short- and long-term recommendations. The main challenges identified relate to the demand for NGS tests (governance, clinical standardization, and awareness and education) and supply of tests (equitable reimbursement, infrastructure for conducting and validating tests, and testing access driven by evidence generation). Recommendations made to resolve each of these challenges should aid multi-stakeholder collaboration between national and European initiatives, to complement, support, and mutually reinforce efforts to improve patient care.
Language:
English
Keywords:
clinical standardization
,
equitable reimbursement
,
European Alliance for Personalised Medicine
,
Europe’s Beating Cancer Plan
,
evidence generation
,
governance
,
molecularly guided treatment options
,
next-generation sequencing
,
stakeholder awareness and education
,
testing infrastructure
Work type:
Article
Typology:
1.01 - Original Scientific Article
Organization:
MF - Faculty of Medicine
Publication status:
Published
Publication version:
Version of Record
Year:
2022
Number of pages:
27 str.
Numbering:
Vol. 12, iss. 1, art. 72
PID:
20.500.12556/RUL-137400
ISSN on article:
2075-4426
DOI:
10.3390/jpm12010072
COBISS.SI-ID:
140518403
Publication date in RUL:
16.06.2022
Views:
600
Downloads:
129
Metadata:
Cite this work
Plain text
BibTeX
EndNote XML
EndNote/Refer
RIS
ABNT
ACM Ref
AMA
APA
Chicago 17th Author-Date
Harvard
IEEE
ISO 690
MLA
Vancouver
:
Copy citation
Share:
Record is a part of a journal
Title:
Journal of personalized medicine
Shortened title:
J. pers. med.
Publisher:
MDPI
ISSN:
2075-4426
COBISS.SI-ID:
31207641
Licences
License:
CC BY 4.0, Creative Commons Attribution 4.0 International
Link:
http://creativecommons.org/licenses/by/4.0/
Description:
This is the standard Creative Commons license that gives others maximum freedom to do what they want with the work as long as they credit the author.
Secondary language
Language:
Slovenian
Keywords:
klinična standardizacija
,
pravično povračilo
,
Evropska zveza za personalizirano medicino
,
Evropski načrt za premagovanje raka
,
pridobivanje dokazov
,
upravljanje
,
molekularno vodene možnosti zdravljenja
,
sekvenciranje naslednje generacije
,
ozaveščanje in izobraževanje deležnikov
,
testiranje infrastrukture
Projects
Funder:
Other - Other funder or multiple funders
Funding programme:
Novartis
Funder:
Other - Other funder or multiple funders
Funding programme:
AstraZeneca
Funder:
Other - Other funder or multiple funders
Funding programme:
F. Hoffmann-La Roche Ltd.
Funder:
Other - Other funder or multiple funders
Funding programme:
Exact Sciences
Funder:
Other - Other funder or multiple funders
Funding programme:
Eli Lilly and Company
Funder:
Other - Other funder or multiple funders
Funding programme:
Illumina
Similar documents
Similar works from RUL:
Similar works from other Slovenian collections:
Back